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Abstract
Fetuses of mothers with gestational diabetes mellitus are at increased
risk to develop perinatal complications mainly due to macrosomia.
However, in view of the marked heterogeneity of this disease, it seems
difficult to set guidelines for diagnosis and treatment. This compli-
cates the choice of assigning patients either to diet or to insulin
therapy. Also of concern is how much benefit could be expected from
insulin therapy in preventing fetal complications in these patients. In
a systematic review of the literature assessing the efficacy of insulin in
preventing macrosomia in fetuses of mothers with gestational diabe-
tes, we found six randomized controlled trials comparing diet alone to
diet plus insulin. The studies included a total of 1281 patients (644 in
the diet plus insulin group and 637 in the diet group), with marked
differences among trials concerning diagnostic criteria, randomiza-
tion process and treatment goals. Meta-analysis of the data resulted in
a risk difference of -0.098 (95%CI: -0.168 to -0.028), and a number-
necessary-to-treat of 11 (95%CI: 6 to 36), which means that it is
necessary to treat 11 patients with insulin to prevent one case of
macrosomia. This indicates a potential benefit of insulin, but not
significantly enough to set treatment guidelines. Because of the het-
erogeneous evidence available in the literature about this matter, we
conclude that larger trials addressing the efficacy of these two thera-
peutic modalities in preventing macrosomia are warranted.
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Gestational diabetes mellitus (GDM) is
defined as carbohydrate intolerance with
onset or first recognition during pregnancy
showing a marked heterogeneity in terms of
the diagnostic and therapeutic approaches.
There is a wide variety of diagnostic criteria
regarding glucose challenge doses and gly-
cemic thresholds (1). Moreover, fetuses of
women with GDM are at increased risk for
perinatal morbidity and mortality, and their
relationship with maternal glycemic control
is more likely to be a continuum rather than a
dichotomous parameter measurable in a sat-
isfactory way by setting a threshold. There
also seems to be great difficulty in establish-
ing therapeutic guidelines for such a hetero-
geneous disease. There is no consensus about
the most effective criterion to be used when
shifting patients from diet alone to insulin
therapy plus diet. The current recommenda-
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tions of the American Diabetes Association
for GDM treatment (2) state that insulin
treatment should be initiated if diet therapy
fails to maintain plasma glucose values equal
to or lower than 5.8, 8.6 and 7.2 mmol/l
under fasting conditions and 1 and 2 h after
meals, respectively. However, these values
are based on observational and retrospective
studies correlating glycemic levels and birth
weight, without assessing the impact of thera-
peutic measures in a randomized and con-
trolled fashion. Even oral hypoglycemic
agents may have effects similar to those of
Table 1. Randomized controlled trials carried out to determine the occurrence of macrosomia in fetuses from mothers with gestational diabetes
treated by diet alone or diet plus insulin.
Randomized controlled trial (reference number)
Coustan and O’Sullivan and Persson Thompson Buchanan Garner
Lewis (5) Mahan (6) et al. (7) et al. (8) et al. (9) et al. (10)
Randomization ND ND Stratified selection Computer generated ND ND
N 38 615 202 68 59 299
Treatment group 27 (2) 307 (16) 97 (11) 34 (2) 30 (4) 149 (24)
(macrosomic newborns observed)
Control group 11 (4) 308 (41) 105 (14) 34 (9) 29 (13) 150 (28)
(macrosomic newborns observed)
Diagnostic criterion - OGTT 5.3/10/8.6 6.1/9.4/6.6 AUC 5.8/10.5/9.1 5.8/-/6.6 -/8/-
(fasting/1 h/2 h) (mM/l) (NDDG)
Macrosomia criterion 3.864 kg 4.09 kg LGA (>90%) 4 kg LGA (>90%) 4 kg
Treatment goals ND ND 5/6.5/- 5.8/-/6.6 3.3-4.4/-/6.1 4.4/7.7/-
(fasting/1 h after meals/2 h after meals)
(mM/l)
Age (diet/diet + insulin) 2 patients >25 years/ ND 29 (18-46)/ 26 ± 5.7/ 30.3 ± 1.1/ 30.7 ± 4.6/
15 patients >25 years  30.5 (16-42) 27 ± 5.4 32.4 ± 1.0 30.7 ± 4.8
Obesity (diet/diet + insulin) 5(45%)/14(52%) ND 22/30 40%/38% ND ND
(>200 lbs)
Insulin type and 20 U NPH + 10 U NPH 8-12 U (NPH or R) 20 U NPH + 1.2 U/kg NPH and R
initial dose 10 U R 10 U R (2/3 before (dosage ND)
in the morning in the morning breakfast +
1/3 before dinner)
Calories (kcal) in diet 30-35 kcal/kg 30 kcal/kg ND 35 kcal/kg 30 kcal/kg 35 kcal/kg
(% carbohydrate/protein/fat) (125 g protein) (40/1.5-2 g/ND) (50/20/30) (50/20/30) (ideal body weight) (%ND)
and 25 kcal/kg
(above ideal)
(50-55/15-20/ND)
AUC = area under the curve; LGA = large for gestational age; ND = not described; NDDG = National Diabetes Data Group; OGTT = oral glucose
tolerance test.
insulin in the treatment of GDM (3). More-
over, the relationship between insulin treat-
ment alone and the incidence of perinatal
complications is unclear.
We performed a systematic review of
randomized controlled trials (RCTs) to as-
sess the influence of the treatment of GDM
with diet plus insulin in comparison with
diet alone on the occurrence of fetal mac-
rosomia. We also assessed secondary out-
comes such as birth weight (as a numerical
parameter), hypoglycemia, hypocalcemia,
hyperbilirubinemia, respiratory distress and
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congenital malformations. We surveyed the
Cochrane Controlled Trials Register, Med-
line, and Lilacs, as well as reference lists of
trials for RCTs published in English, Span-
ish or Portuguese using the term “diabetes,
gestational” combined with the strategy pro-
vided in the Cochrane Reviewers’ Hand-
book (4), from 1972 to December 2001. The
trials retrieved were selected by reading their
abstracts or the entire trial when necessary.
This review used RCTs that compared diet
alone with diet plus insulin in pregnant
women with GDM, regardless of random-
ization method or diagnostic criterion. Our
primary goal was to determine the incidence
of fetal macrosomia.
Of the 476 trials using this search strat-
egy, only six (5-10) were RCTs which com-
pared diet alone to diet plus insulin in the
treatment of GDM and contained informa-
tion about macrosomia (Table 1). We ex-
cluded RCTs performing the same interven-
tions but with no information about the de-
sired outcomes, RCTs performing other in-
terventions and studies that were not RCTs.
The total number of patients reviewed
was 1281. For macrosomia, risk difference,
Petto odds ratio, odds ratio and relative risk
analyses favored treatment. Risk difference
was -0.098 (95%CI: -0.168 to -0.028) and
number-necessary-to-treat was 11 (95%CI:
6 to 36; Table 2). Other fetal complications
of GDM such as hypoglycemia, hypocalce-
mia, hyperbilirubinemia and congenital mal-
formations showed no statistically signifi-
cant differences between the two groups.
The results obtained in this review of the
literature show the potential benefit of insu-
lin plus diet for the treatment of GDM in
decreasing the incidence of macrosomia com-
pared to diet alone. Nevertheless, method-
ological problems such as small samples and
inadequately described randomization should
be solved in larger trials with more adequate
randomization and blinding. The external
validity of the trials was also impaired by
discrepancies involving diagnostic criteria,
initial characteristics of patients and defini-
tion of the outcomes reviewed. The hetero-
geneity of these trials impaired the statistical
quality of the conclusions of this review.
We conclude that although this review
indicates a trend in favor of insulin treat-
ment, this trend is not strong enough to
Table 2. Meta-analysis of effects of insulin treatment on the incidence of macrosomia in the included randomized controlled trials.
Randomized Experimental Control Weight Risk difference Risk difference
controlled trial (n/N) (n/N) (%) (95%CI random) (95%CI random)
Buchanan et al. (9) 4/30 13/29 8.0 -0.315 (-0.533, -0.097)
Coustan and Lewis (5) 2/27 4/11 4.7 -0.290 (-0.591, 0.011)
Garner et al. (10) 24/149 28/150 23.0 -0.026 (-0.111, 0.060)
O’Sullivan and Mahan (6) 16/307 41/308 30.5 -0.081 (-0.126, -0.036)
Persson et al. (7) 11/97 14/105 22.1 -0.020 (-0.111, 0.071)
Thompson et al. (8) 2/34 9/34 11.7 -0.206 (-0.374, -0.038)
Total  (95%CI) 59/644 109/637 100.0 -0.098 (-0.168, -0.028)
Chi-square 11.73 (d.f. = 5) Z = 2.73
-1 0 1
Favors Favors
treatment control
Comparison: diet vs diet + insulin. Outcome: macrosomia.
CI = confidence interval; n = number of macrosomic newborns observed; N = number of individuals treated in each group.
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modify current clinical practice. It was not
possible to set guidelines for the treatment of
GDM, not only because of the heterogeneity
of the trials reviewed, but also because of the
heterogeneity in the definition of GDM it-
self. Moreover, the tendency to treat each
case individually is inherent to the treatment
of diabetes, further preventing a standardized
approach. New RCTs with larger samples
and following current diagnostic criteria (2)
are necessary to answer these questions.
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